Royce Micro-Cap Fund Manager Commentary
article 08-07-2024

Royce Micro-Cap Fund Manager Commentary

The Fund gained 2.6% for the year-to-date period ended 6/30/24, outperforming its primary benchmark, the Russell Microcap Index, which was down -0.8%, and the Russell 2000 Index, which rose 1.7% for the same period. The Fund also beat its benchmark for the 1-, 3-, 5-, 10-, and 20-year periods ended 6/30/24.

TELL US
WHAT YOU
THINK

Fund Performance

Royce Micro-Cap Fund advanced 2.6% for the year-to-date period ended 6/30/24, outperforming its primary benchmark, the Russell Microcap Index, which was down -0.8%, and the Russell 2000 Index, which rose 1.7% for the same period. The Fund also beat its benchmark for the 1-, 3-, 5-, 10-, and 20-year periods ended 6/30/24 and outperformed the Russell 2000 for the 1-, 3-, 5-, 25-, 30-year, and since inception (12/31/91) periods ended 6/30/24.

What Worked... and What Didn’t

Six of the portfolio’s 10 equity sectors made a positive impact on year-to-date period performance. The sectors making the largest positive contributions were Industrials, Materials, and Energy while the largest negative impacts came from Financials, Consumer Discretionary, and Information Technology. At the industry level, commercial services & supplies (Industrials), semiconductors & semiconductor equipment (Information Technology), and electrical equipment (Industrials) contributed most for the year-to-date period, while communications equipment (Information Technology), banks (Financials), and specialty retail (Consumer Discretionary) were the largest detractors.

The Fund’s top contributor at the position level was American Superconductor, which supplies advanced technologies designed to enhance energy efficiency across power grids, wind power, and military applications. As the market has increasingly recognized the significant power needs associated with Artificial Intelligence (“AI”) and Electric Vehicles “EVs)”, it has come to see the company as a potentially significant supplier into that energy ecosystem. IES Holdings designs and installs electrical and technology systems into numerous infrastructure segments, including residential housing, commercial buildings, and data centers. Through a thoughtful growth strategy focused on both internal and external opportunities, IES has slowly built scale in each of its four business segments. This has resulted in rapidly improving operating profitability, driving strong growth in earnings before interest, taxes, depreciation & amortization (“EBITDA”). As a company with very little research coverage, IES flew under the radar of most investors, though more began to take note of the company’s improved profitability in 2024’s first half.

Modine Manufacturing, which provides thermal management products and solutions has been transitioning from commoditized products focused on the auto industry to more value-added solutions that target better opportunities in areas such as data center construction and Electric Vehicles (EVs). The stock currently reflects the rapid acceleration in data center construction around demand for AI applications. Camtek designs and manufactures high-end metrology and inspection systems for the semiconductor industry. Both of these systems have become increasingly important parts of the semiconductor supply chain as semiconductors have become increasingly complex, a trend that has been accelerated by the demands for High Band Width Memory associated with Artificial Intelligence applications. Camtek is one of the few companies with the technology to meet these increasing demands. Aspen Aerogels designs and manufactures aerogel insulation products that have many applications for industrial uses, but most importantly for use in EVs. “Thermal runaway,” the phenomenon in which the lithium-ion battery cell enters an uncontrollable, self-heating state causing a vehicle to catch on fire. Aspen’s PyroThin Technology has earned a reputation for preventing thermal runaway, which has been reflected in the number of critical wins for its products in the EV space. After a period of significant investment in building out manufacturing capacity, the company is beginning to ramp production at scale, which in turn is driving strong growth in revenues and operating profitability. We see a very long runway for the company’s technology as EV adoption continues to grow. Each contributor was also a top performer relative to the Russell Microcap Index.

The Fund’s top detractor at the position level was Applied Optoelectronics, which manufactures optical products and components. Its stock rose high in 2023 on the back of a large contract win with Microsoft, which coincided with market enthusiasm for AI opportunities. We think its underwhelming performance so far in 2024 reflects a typical correction. We also believe that we are still in the early stages of the buildout of AI applications and that having Microsoft as a lead account should help Applied Optoelectronics benefit going forward. Harvard Biosciences makes instrumentation products used in clinical and educational healthcare settings and is in the midst of a turnaround focused on rationalizing its product portfolio and reallocating research and development investments to higher growth opportunities. Business results have been hurt by the lingering impacts of Covid and the slowdown in the Chinese economy. As is often the case with micro-cap turnarounds, progress has been slower than initially hoped for, but we believe the company is well positioned to drive accelerating revenue growth and profitability over the intermediate term.

Luna Innovations provides optical test and measurement services. The company ran into serious accounting issues that resulted in a rapid decline in its share price. Normally, we would be sellers of any stock after such a dramatic and unexpected turn. However, Luna’s Board of Directors acted decisively, bringing in an experienced management team. Moreover, our underlying investment case centered on what we believe is highly promising technology that should ultimately provide asset support to the shares. Given the immediate share price reaction and what we view as solid underlying asset collateral, we decided to hold our position until we have more clarity on the underlying accounting issues. Aehr Test Systems provides semiconductor testing equipment that provides unique capabilities for testing where the cost of failure is quite high. While originally a niche product, opportunities began to expand rapidly as semiconductor content became more mission critical, particularly in EVs. After a significant period of adoption of Aehr’s test equipment, there has been a lull as EV adoption has slowed and its customers work to increase the utilization of their existing tools. We see a very open-ended opportunity for Aehr and thus chose to maintain our position. Beyond is an internet retailer that had historically been focused on higher price point home and garden products. After buying the rights to the Bed Bath and Beyond brand out of bankruptcy, the company became a much broader based e-commerce retailer. The integration of the Bed Bath and Beyond brand has proven more challenging than originally anticipated, however, while sales of higher priced outdoor furniture remains challenged as a reflection of a Covid hangover. We continue to believe in the company’s decision to broaden its home based retail strategy and therefore maintained our position.

The portfolio’s advantage over the Russell Microcap came mostly from stock selection in the year-to-date period. At the sector level, both stock selection and our higher weighting boosted relative results in Industrials, as did stock selection in both Materials and Communication Services. Conversely, the portfolio’s significantly lower exposure to Health Care, stock selection in Consumer Discretionary, and lower weight in Consumer Staples detracted most from relative results in 2024’s first half.


Top Contributors to Performance Year-to-Date Through 6/30/241

American Superconductor
IES Holdings
Modine Manufacturing
Camtek
Aspen Aerogels

1 Includes dividends

Top Detractors from Performance Year-to-Date Through 6/30/242

Applied Optoelectronics
Harvard Bioscience
Luna Innovations
Aehr Test Systems
Beyond

2 Net of dividends

Current Positioning and Outlook

Being a micro-cap investor has recently felt like being in an extended production of Waiting for Godot. The market remains focused on when—or if—the Fed will begin to lower rates, and by how much. While earnings for the companies in the portfolio have remained generally solid, it is increasingly clear the economy and inflation are slowing. The market remains hyper-focused on each day-to-day release of economic data, but we remain focused on what we see as significant intermediate-term opportunities for our holdings. We believe we are in the early innings of secular changes related to opportunities such as the reshoring of U.S. industrial capacity, increased infrastructure spending, and the increased use cases around artificial intelligence, among other technologies. We expect these trends to benefit the “picks and shovel” providers in our portfolio for years to come. Lastly, we would be remiss if we ignored the increasing political uncertainty in the U.S. and throughout the world. As noted, we generally embrace short-term volatility as a longer-term investment opportunity, but the unsettled political environment seems to be increasing potential black swan events.

Average Annual Total Returns Through 06/30/24 (%)

QTR1 YTD1 1YR 3YR 5YR 10YR 15YR 20YR 25YR 30YR SINCE INCEPT.
(12/31/91)
Micro-Cap -1.742.6411.92-0.2711.135.898.577.069.069.5910.37
Russell Microcap -5.27-0.845.96-7.855.555.5310.166.10N/AN/AN/A

Annual Operating Expenses: Gross 1.25 Net 1.24

1 Not annualized.

Important Performance, Expense and Disclosure Information

Important Performance and Expense Information

All performance information reflects past performance, is presented on a total return basis, reflects the reinvestment of distributions, and does not reflect the deduction of taxes that a shareholder would pay on fund distributions or the redemption of fund shares. Past performance is no guarantee of future results. Investment return and principal value of an investment will fluctuate, so that shares may be worth more or less than their original cost when redeemed. Current month-end performance may be higher or lower than performance quoted and may be obtained at www.royceinvest.com. Gross operating expenses reflect the Fund's total gross annual operating expenses for the Investment Class and include management fees and other expenses. Net operating expenses reflect contractual fee waivers and/or expense reimbursements. All expense information is reported as of the Fund's most current prospectus. Royce & Associates has contractually agreed, without right of termination, to waive fees and/or reimburse expenses to the extent necessary to maintain the Investment Class's net annual operating expenses (excluding brokerage commissions, taxes, interest, litigation expenses, acquired fund fees and expenses, and other expenses not borne in the ordinary course of business) at or below 1.24% through April 30, 2025.

Current month-end performance may be obtained at our Prices and Performance page.

Notes to Performance and Other Important Information

The thoughts expressed in this report concerning recent market movements and future prospects for small company stocks are solely the opinion of Royce at June 30, 2024, and, of course, historical market trends are not necessarily indicative of future market movements. Statements regarding the future prospects for particular securities held in the Funds’ portfolios and Royce’s investment intentions with respect to those securities reflect Royce’s opinions as of June 30, 2024 and are subject to change at any time without notice. There can be no assurance that securities mentioned in this report will be included in any Royce-managed portfolio in the future.


As of 6/30/24, the percentage of Fund assets was as follows: American Superconductor was 1.3%, IES Holdings was 1.0%, Modine Manufacturing was 1.1%, Camtek was 1.1%, Aspen Aerogels was 0.6%, Applied Optoelectronics was 0.6%, Harvard Bioscience was 0.6%, Luna Innovations was 0.5%, Aehr Test Systems was 0.4%, Beyond was 0.5%.


Sector weightings are determined using the Global Industry Classification Standard (“GICS”). GICS was developed by, and is the exclusive property of, Standard & Poor’s Financial Services LLC (“S&P”) and MSCI Inc. (“MSCI”). GICS is the trademark of S&P and MSCI. “Global Industry Classification Standard (GICS)” and “GICS Direct” are service marks of S&P and MSCI.

All indexes referred to are unmanaged and capitalization weighted. Each index’s returns include net reinvested dividends and/or interest income. Russell Company (“Russell”) is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell’s express written consent. Russell does not promote, sponsor or endorse the content of this communication. The Russell 2000 Index is an index of domestic small-cap stocks. It measures the performance of the 2,000 smallest publicly traded U.S. companies in the Russell 3000 Index. The Russell 2000 Value and Growth Indexes consist of the respective value and growth stocks within the Russell 2000 as determined by Russell Investments. The Russell Microcap Index includes 1,000 of the smallest securities in the Russell 2000 Index, along with the next smallest eligible securities as determined by Russell. The Russell 2500 is an unmanaged, capitalization-weighted index of the 2,500 smallest publicly traded U.S. companies in the Russell 3000 index. The returns for the Russell 2500-Financial Sector represent those of the financial services companies within the Russell 2500 index. Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The MSCI ACWI Small Cap Index is an unmanaged, capitalization-weighted index of global small-cap stocks.The MSCI ACWI ex USA Small Cap Index is an index of global small-cap stocks, excluding the United States.The performance of an index does not represent exactly any particular investment, as you cannot invest directly in an index. Returns for the market indexes used in this report were based on information supplied to Royce by Russell Investments. Royce has not independently verified the above described information.

This material contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve risks and uncertainties, including, among others, statements as to:

-the Funds’ future operating results,

-the prospects of the Funds’ portfolio companies,

-the impact of investments that the Funds have made or may make, the dependence of the Funds’ future success on the general economy and its impact on the companies and industries in which the Funds invest, and

-the ability of the Funds’ portfolio companies to achieve their objectives.

This discussion uses words such as “anticipates,” “believes,” “expects,” “future,” “intends,” and similar expressions to identify forward-looking statements. Actual results may differ materially from those projected in the forward-looking statements for any reason.

The Royce Funds have based the forward-looking statements included in this commentary on information available to us on the date of the commentary, and we assume no obligation to update any such forward-looking statements. Although The Royce Funds undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise, you are advised to consult any additional disclosures that we may make through future shareholder communications or reports.

This material is not authorized for distribution unless preceded or accompanied by a current prospectus. Please read the prospectus carefully before investing or sending money. Smaller-cap stocks may involve considerably more risk than larger-cap stocks. (Please see “Primary Risks for Fund Investors” in the prospectus.)

Share:

Subscribe:

Sign Up

Follow: